[3PS-266]
Microspheres for Sustained Release of Anti-VEGF Drugs in Treating Subfoveal Choroidal Neovascularization
발표자김강민 (성균관대학교)
연구책임자정지훈 (성균관대학교)
Abstract
Age-related macular degeneration (AMD) is a leading cause of vision loss, primarily driven by pathological neovascularization mediated by the vascular endothelial growth factor (VEGF) pathway. This study investigates the therapeutic potential of sustained-release microspheres formulated with poly(lactic-co-glycolic acid) (PLGA) for controlled delivery of the anti-VEGF drug, Rivoceranib. Rivoceranib was encapsulated using an oil-in-water (o/w) single emulsion method followed by solvent evaporation. In vivo experiments utilizing a laser-induced choroidal neovascularization (CNV) mouse model demonstrated that Rivoceranib-loaded PLGA microspheres significantly suppressed neovascularization. These findings suggest that sustained-release PLGA microspheres containing Rivoceranib could serve as an innovative strategy for treating wet AMD through drug repositioning, offering prolonged efficacy and reduced administration frequency.